NeuroDex

Executive Summary

NeuroDex is a Boston-based biotechnology company pioneering precision neurology diagnostics through its proprietary neuron-derived exosome (NDE) platform. The company focuses on discovering and validating biomarkers for neurological disorders such as Parkinson's, Alzheimer's, and ALS. By leveraging the molecular cargo of neuron-derived exosomes isolated from blood, NeuroDex aims to enable early disease detection, monitor treatment response, and accelerate drug development. Since its founding in 2019, the company has remained in the pre-clinical stage, building its technology foundation and establishing its biomarker panels. Despite the promise of its NDE platform, NeuroDex faces significant challenges typical of early-stage diagnostics companies, including the need for large-scale clinical validation, regulatory clearance, and commercial adoption. The platform's ability to deliver reproducible, minimally invasive liquid biopsy solutions for neurology could address a substantial unmet need, as current diagnostic tools for these conditions are limited. The company's progress will depend on generating robust clinical data, securing partnerships with pharmaceutical firms, and navigating the complex regulatory landscape for biomarker-based diagnostics.

Upcoming Catalysts (preview)

• Q1 2027Initiation of first-in-human clinical trial for Parkinson's disease biomarker test50% success
• Q3 2026Publication of clinical validation study in peer-reviewed journal70% success
• Q4 2026Strategic partnership with pharmaceutical company for ALS biomarker development30% success